reports
Genocea Announces Wind Down of Operations and Delisting From NASDAQ
Genocea Announces Wind Down of Operations and Delisting From NASDAQ CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board of Directors voted to wind down the Company’s ongoing operations and terminate the Company’s remaining employees except those deemed necessary to complete an orderly wind down. On May 23, 2022, the Company delivered formal notice to The Nasdaq Stock Market, Inc. of its intent to voluntarily delist its Common Stock from the ...
Genocea Initiates Restructuring and Announces Plan to Explore Strategi...
Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and has engaged professional advisors, including an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of the Company,...
Genocea Biosciences to Host Investor Webinar
Genocea Biosciences to Host Investor Webinar CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced details for a planned investor webinar to coincide with the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13. The presentation, beginning at 4:30 PM EDT on Friday, April 8th will be followed by a Q&A session. The Genocea team will discuss , including late-breaking data from the TiTAN™ clinical trial for the neoantigen-targeted peripher...
Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conferenc...
Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17th at 8:40 A.M. ET. A live webcast of the presentation will be available under the "Events and Presentations" tab of the investor relations section of the Genocea website at . A replay of t...
Genocea Provides Fourth Quarter 2021 Corporate Update
Genocea Provides Fourth Quarter 2021 Corporate Update Initial GEN-011 clinical trial data to be presented at AACR Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the fourth quarter ended December 31, 2021. GEN-011 TiTAN™ trial update Genocea is conducting the Phase I/2a TiTAN clinical trial for its lead program GEN-011, a neoantigen-targeted peripheral T cell (NPT) therapy ca...
Genocea to Present Clinical and Preclinical Data at AACR Annual Meetin...
Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea’s neoantigen-targeted peripheral T cell therapy for solid tumors The PLANET manufacturing process reliably generates abundant, high-quality neoantigen-specific T cellsPreclinical data indicate that Inhibigens™ accelerate tumor growth in animal models of pancreatic cancer and melanoma CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immun...
John Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of Direc...
John Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of Directors CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that John Lunger, Chief Patient Supply Officer at Adaptimmune Therapeutics plc ("Adaptimmune"), has joined its board of directors. “It is my pleasure to welcome John to our board of directors,” said Chip Clark, Genocea’s President and Chief Executive Officer. "Scaling our technical operations to ensure the reliable delive...
Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call &...
Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, March 10th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 1066689. To join the live webcast, please vi...
Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Co...
Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17th at 10:40 A.M. ET. A live webcast of the presentation will be available in the "Events and Presentations" tab of the investor relations section of the Genocea webs...
Genocea to Present at Upcoming Investor Conferences
Genocea to Present at Upcoming Investor Conferences CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January. Conferences: Event:Longwood Healthcare Leaders Winter Webconference - Topic 1:Innovation in Cell TherapyFormat:PanelDate:Thursday, January 6, 2022Time:1:30 PM ETTopic 2:Making a Big Impact With Limited ResourcesFormat:Date:Time:PanelThursday, January 6, 20225:10 PM ETEvent:LifeSci Partners 11...
Genocea Biosciences Provides Corporate Update
Genocea Biosciences Provides Corporate Update Enters into Inhibigen™ R&D collaboration and option agreement with Janssen Reports progress on the GEN-011 TiTAN™ trial CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, has entered into an R&D collaboration and option agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to explore the immunogenicity of neoantigens and the role and impact of Inhibigens™ in the contex...
Genocea to Present at the Stifel 2021 Virtual Healthcare Conference
Genocea to Present at the Stifel 2021 Virtual Healthcare Conference CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17th at 1:20 PM ET. A live webcast of the presentation can be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at . A replay of th...
Genocea Provides Third Quarter 2021 Corporate Update
Genocea Provides Third Quarter 2021 Corporate Update GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues Strong presence at the SITC 36th Annual Meeting Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the third quarter ended September 30, 2021. “We continue to make significant progress. Most notably, we are very excited about our TiTAN™ clinical trial for GEN-011, our neo...
Genocea to Host Third Quarter 2021 Corporate Update Conference Call & ...
Genocea to Host Third Quarter 2021 Corporate Update Conference Call & Webcast CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its third quarter 2021 corporate update conference call and live audio webcast on Thursday, October 28th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 8729366. To join the live webcast, please visit the presentation page o...
Genocea to Present at Upcoming Conferences
Genocea to Present at Upcoming Conferences CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in October. Scientific conferences: Event:AACR: Tumor Immunology and Immunotherapy – Topic:GEN-011: A neoantigen-targeted peripheral blood-derived T cell therapy that has broad neoantigen specificity and high T cell purity while avoiding pro-tumor cellsFormat:Poster presentationDate:Tuesday-Wednesday, October 5-6thTim...
Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board...
Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Jennifer Herron, Senior Vice President & Chief Commercial Officer at ADC Therapeutics SA ("ADCT"), has joined its board of directors. “It is my great pleasure to welcome Jennifer to our board of directors,” said Chip Clark, Genocea’s President and Chief Executive Officer. "As we advance our pipeline, including...
Genocea to Present at Upcoming Scientific and Investor Conferences
Genocea to Present at Upcoming Scientific and Investor Conferences CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following virtual conferences in September. Scientific conferences: Event:Next Generation Cancer Vaccine Development Summit – Topic:Neoantigen selection to identify immunogenic tumor specific targets personalized to each patient’s tumor and immune systemFormat:Post Conference WorkshopDate:Thursday, September 9thTime...
Genocea Provides Second Quarter 2021 Corporate Update
Genocea Provides Second Quarter 2021 Corporate Update GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues GEN-009 neoantigen vaccine candidate shows promising long-term clinical results Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the second quarter ended June 30, 2021. “I am pleased with the GEN-011 program progress. We continue to believe that GEN-011 has the potential to re...
Genocea to Host Second Quarter 2021 Corporate Update Conference Call &...
Genocea to Host Second Quarter 2021 Corporate Update Conference Call & Webcast CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its second quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, July 29th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 6789021. To join the li...
Genocea Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN...
Genocea Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN-011 Neoantigen-Targeted T cell Therapy CAMBRIDGE, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the dosing of the first patient in its TiTAN study, a Phase 1/2a clinical trial testing its GEN-011 therapy. GEN-011 represents a new category of autologous solid tumor cell therapy: neoantigen-targeted peripheral T cells (“NPTs”). “Dosing the first patient with GEN-011 represents an exciti...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.